In a busy week for Dr. Reddy’s Laboratories, the company has completed its acquisition of The Dow Chemical Company’s Dowpharma Small Molecules Business along with its Mirfield and Cambridge, UK sites. Financial terms of the transaction were not disclosed.
   
The acquisition includes the relevant business, customer contracts, associated products, process technology, intellectual property and trademarks, as well as the transfer of the Mirfield and Cambridge facilities. Employees directly related to the business at each site will become part of Dr Reddy’s. Dr. Reddy’s will also have a non-exclusive license to Dow’s Pfenex Expression Technology for biocatalysis development.